Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-010716
Filing Date
2022-07-14
Accepted
2022-07-14 16:15:52
Documents
35
Period of Report
2022-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20220531x10q.htm   iXBRL 10-Q 460786
2 EX-31.1 bzyr-20220531xex31d1.htm EX-31.1 11663
3 EX-31.2 bzyr-20220531xex31d2.htm EX-31.2 11947
4 EX-32.1 bzyr-20220531xex32d1.htm EX-32.1 6685
5 EX-32.2 bzyr-20220531xex32d2.htm EX-32.2 7115
  Complete submission text file 0001558370-22-010716.txt   1775764

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20220531.xsd EX-101.SCH 19088
7 EX-101.CAL bzyr-20220531_cal.xml EX-101.CAL 17158
8 EX-101.DEF bzyr-20220531_def.xml EX-101.DEF 47857
9 EX-101.LAB bzyr-20220531_lab.xml EX-101.LAB 155634
10 EX-101.PRE bzyr-20220531_pre.xml EX-101.PRE 96690
29 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20220531x10q_htm.xml XML 140982
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0228
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 221083213
SIC: 2835 In Vitro & In Vivo Diagnostic Substances